

89. (new) The method of Claim 63 in which the condition is a bacterial infection.

90. (new) The method of Claim 63 in which the condition is a parasitic infection.

91. (new) The method of Claim 63 which further comprises administering to an individual an effective amount of anti-TNF α , anti-IL-1, anti-IFN- γ , IL-1RA, a steroid, a glucocorticoid, or IL-10.

92. (new) The method for enhancing the anti-inflammatory activity of a therapeutic steroid comprising administering to an individual an effective amount of an agent that modulates MIF gene expression and the therapeutic steroid.

93. (new) The method for reducing the toxic side effects of a therapeutic steroid comprising administering to an individual an agent that modulates MIF gene expression and the therapeutic steroid. --

REMARKS

In response to the Restriction Requirement, the Applicants hereby elect Group I (Claims 63-64). Claims 65-79, covering the non-elected subject matter, are canceled without prejudice to the Applicants' right to pursue the subject matter in other applications. New Claims 80-93 correspond to

the elected subject matter and are fully supported by the application and claims as originally filed.

Entry of the foregoing amendments and remarks is respectfully requested. An early allowance is earnestly sought.

Respectfully submitted,

Date June 25, 1996

 30,742
Laura A. Coruzzi (Reg. No.)

PENNIE & EDMONDS
1155 Avenue of the Americas
New York, New York 10036-2711
(212) 790-9090